For Healthcare Professionals

Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy


About the study

The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Male or non-pregnant, non-lactating female, age 12 to 65 years who have satisfactorily completed study LP352-201
  2. Diagnosis of Dravet syndrome, Lennox-Gastaut syndrome, or other developmental and epileptic encephalopathy
  3. The patient/parent/caregiver is able and willing to attend study visits, complete the diary and take study drug as instructed


Exclusion Criteria:

  1. Had an SAE in Study LP352-201 that was definitely, probably, or possibly related to exposure to study drug
  2. Current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction, stroke, pulmonary arterial hypertension or abnormal blood pressure
  3. Has glaucoma, renal impairment, liver disease or any other medical condition that would affect study participation or pose a risk to the subject
  4. Current or recent history of moderate or severe depression, anorexia nervosa, bulimia or at risk of suicidal behavior
  5. Currently taking anorectic agents, monoamine oxidase inhibitors; serotonin agonists or antagonists including fenfluramine, atomoxetine, vortioxetine, or other medications for weight loss
  6. Positive test result on the drug screen, except tetrahydrocannabinol (THC) for patients taking prescribed cannabidiol
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Developmental and Epileptic Encephalopathy,Dravet Syndrome,Lennox-Gastaut Syndrome

Age (in years)

12 - 65


Phase 2

Participants needed


Est. Completion Date

Oct 31, 2024

Treatment type



Longboard Pharmaceuticals identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.